Korean J Psychopharmacol.
2011 Jan;22(1):29-33.
Cost of Relapse in Patients with Schizophrenia in Korea
- Affiliations
-
- 1Department of Psychiatry, Seoul National University College of Medicine, Seoul, Korea. kwonjs@plaza.snu.ac.kr
- 2Department of Psychiatry, Seoul Paik Hospital, Inje University College of Medicine, Seoul, Korea.
- 3Stress Research Institute, Inje University, Seoul, Korea.
- 4Brain & Cognitive Science-WCU Program, Seoul National University College of Natural Sciences, Seoul, Korea.
Abstract
OBJECTIVE
The aims of this study were to quantify the costs of treatment in patients with schizophrenia and to compare the cost according to the relapse status.
METHODS
A total of 330 patients were consecutively enrolled from 11 hospitals in Korea. Differences in direct medical costs by relapse status in the 6 months were examined.
RESULTS
The medical cost in patients with relapse was about seven times higher than the cost in patients without relapse. The cost for hospitalization largely accounted for the cost in patients who relapsed. The most common reason for the hospitalization in patients with relapse was poor drug compliance.
CONCLUSION
Relapse in patients with schizophrenia significantly increases medical costs in Korea.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Cost Effectiveness of Clozapine and Risperidone in
- Cost-Utility Analysis of Paliperidone Palmitate Long Acting Injection (PLAI) versus Oral Atypical Antipsychotics in Non-Adherent Schizophrenia Patients in South Korea
- One-year Follow-up of the Hospitalized Schizophrenic Patients Treated with Risperidone or Olanzapine: Aspects in Cost Economy
- Cost-Effectiveness of Clozapine Treatment for Patients with Refractory Schizophrenia
- Direct and Indirect Cost of Treating Out-Patients with Schizophrenia in Korea
